Drug Profile

Ibcasertib - Chipscreen Biosciences

Alternative Names: Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor; Chiauranib; Chiauranib - Chipscreen Biosciences; CS-2164; Ibcasertib

Latest Information Update: 08 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chipscreen Biosciences
Developer Akeso Biopharma; Chipscreen Biosciences
Class Amides; Aniline compounds; Antineoplastics; Ethers; Naphthalenes; Quinolines; Small molecules
Mechanism of Action Angiogenesis inhibitors; Aurora kinase B inhibitors; Macrophage colony-stimulating factor receptor antagonists; Mitosis inhibitors; Platelet-derived growth factor alpha receptor antagonists; Proto-oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Small cell lung cancer
New Molecular Entity Yes

Phase III Ovarian cancer; Peritoneal cancer; Small cell lung cancer
Phase II Adenocarcinoma; Graft-versus-host disease; Non-Hodgkin's lymphoma; Soft tissue sarcoma; Triple negative breast cancer
Phase I/II Liver cancer
Preclinical Pancreatic cancer
No development reported Solid tumours

08 Nov 2024 Chipscreen Biosciences plans a phase III trial in Small-cell lung cancer (First-line therapy) (PO, Capsule)
05 Nov 2024 Chipscreen Biosciences terminates a phase II trial in Triple-negative-breast cancer (Combination therapy, Second-line therapy or greater, Metastatic disease, Late-stage disease) in China (PO) as during the enrollment period of this project, due to the increasing proportion of patients receiving capecitabine adjuvant therapy and the large number of trials competing for the same number of lines in various centers (NCT05336721)
01 Nov 2024 Chipscreen Biosciences receives Drug Clinical Trial Approval Notice from the NMPA for Ibcasertib in Small cell lung cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com